ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
May 27 2024 - 12:00PM
Business Wire
Article L233-8-II of the French Commercial
Code Article 223-16 of the General Regulations of the AMF
(French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market: Euronext Paris, Compartment C ISIN code:
FR0012616852
Date
Number of shares outstanding
Total voting rights
Total gross (1)
Total net (2)
May 22, 2024
32,459,012
32,459,012
32,202,449
(1) The total number of gross (or “theoretical”) voting rights
is used as the basis for calculating threshold crossings. In
accordance with Article 223-11 of the AMF General Regulations, this
number is calculated on the basis of all shares to which voting
rights are attached, including those for which voting rights have
been suspended.
(2) The total number of net (or “exercisable at a Shareholders’
Meeting”) voting rights is calculated without taking into account
shares for which voting rights have been suspended. It is released
in order to ensure that the public is properly informed, in
accordance with the recommendation made by the AMF on 17 July
2007.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines in diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated apoA-I
-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240527248453/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Abionyx Pharma (EU:ABNX)
Historical Stock Chart
From Aug 2023 to Aug 2024